CliffBio
small molecule

LIBRELEASE

CHLORDIAZEPOXIDE

Loss of exclusivity—loss of exclusivity
CompanyVALEANT PHARMACEUTICALS INTERNATIONAL

Drug detail

Brand nameLIBRELEASE
Active ingredientCHLORDIAZEPOXIDE
Strength30MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 1983
Marketing statusDISCN

More from VALEANT PHARMACEUTICALS INTERNATIONAL

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

LIBRELEASE patent cliff — loss of exclusivity — | CliffBio